Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow PFE
Pfizer Inc. (PFE) EV/FCF
As of 9 October 2026, Pfizer Inc. (PFE) trades at a EV/FCF of 20.9×. Over the past ten years it has ranged from 8.4× (October 2021) to 59.9× (July 2024); the current reading is higher than 74% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 23.3× | 8.38% |
| FY2024 | 21.5× | (62.19%) |
| FY2023 | 56.8× | 377.05% |
| FY2022 | 11.9× | 2.42% |
| FY2021 | 11.6× | (42.98%) |
| FY2020 | 20.4× | (17.23%) |
| FY2019 | 24.6× | 26.81% |
| FY2018 | 19.4× | 22.62% |
| FY2017 | 15.8× | 4.30% |
| FY2016 | 15.2× | (2.12%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 18.5× | (23.81%) |
| Mar 2026 | 24.3× | 4.44% |
| Dec 2025 | 23.3× | 16.40% |
| Sep 2025 | 20.0× | 24.94% |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNY Sanofi compare | 7.8× |
| BMY Bristol Myers Squibb Company compare | 13.4× |
| GSK GSK PLC Sponsored ADR compare | 14.8× |
| GILD Gilead Sciences, Inc. compare | 16.3× |
| NVS Novartis AG compare | 20.6× |
| PFE Pfizer Inc. | 20.9× |
| NVO Novo Nordisk A/S compare | 24.4× |
| AMGN Amgen Inc. compare | 27.4× |
| AZN AstraZeneca PLC compare | 43.3× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement